Can a drug and probiotic combo turn back the clock on aging?

NCT ID NCT07363057

Recruiting now Disease control Sponsor: GI Innovation, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether a combination of a drug (GI-102) and a probiotic supplement (GIB-7) can improve markers of aging in the immune system. The study includes 15 healthy adults and cancer survivors aged 18 to 80. Participants will receive either the active combination or a placebo for 8 weeks, and researchers will measure changes in immune cells, sleep quality, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GI-102 (efzilonkofusp alfa) plus GIB-7 (synbiotic formula)
What this could lead to: If successful, this could point toward a treatment that slows or reverses some aspects of immune aging, potentially improving health in older adults and cancer survivors.
What could go wrong: This is a very small early-phase trial with only 15 participants, so results may not apply broadly. The combination therapy is new, and side effects or lack of effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER SURVIVORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER SURVIVORS ELDERLY HEALTHY PARTICIPANT

Contacts and locations

Locations

Novatrials
RECRUITING

Charlestown, New South Wales, 2290, Australia
Southern Oncology Clinical Research Unit
RECRUITING

Adelaide, South Australia, 5042, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.